Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

NCT05470413 is registered in ClinicalTrials.gov with Reistone Biopharma Company Limited as lead sponsor.

NCT NCT05470413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05470413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
Lead sponsor
Reistone Biopharma Company Limited
Phase
Phase 3
Overall status
Unknown status
Start date
April 18, 2022
Completion date
February 15, 2024
Enrollment
330 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata